# Evidence Summary
Itraconazole is one of the better-known **drug-repurposing candidates** in oncology because it combines broad pathway relevance with an established non-cancer medical history.
### Research Overview
1. Multiple pathway-based studies support Hedgehog, angiogenesis, AKT / mTOR, Wnt / β-catenin, and multidrug-resistance effects
2. Early clinical data exists in metastatic prostate cancer, NSCLC, and basal cell carcinoma
3. Retrospective combination studies suggest meaningful signal in ovarian, breast, and pancreatic cancer settings
4. Clinical oncology data is promising but still limited by size, design, and heterogeneity
5. Most evidence supports adjunctive or combination use rather than standalone use
### Clinical Application Status
**Approved status:** Approved as an antifungal medicine, not as an approved cancer drug.
**Clinical use:** Used experimentally in repurposed-drug and investigational oncology strategies.
**Evidence strength:** Moderate, with meaningful early human signals but limited large randomised oncology trials.
### Key Advantages
1. **Multi-pathway action** — inhibits several oncogenic survival pathways at once
2. **Anti-angiogenic relevance** — especially through VEGFR2-related effects
3. **Repurposed-drug practicality** — already globally available as a known medicine
4. **Combination potential** — often explored alongside standard chemotherapy
5. **Favourable baseline safety familiarity** — relative to novel experimental agents
### Key Considerations
1. **Clinical evidence remains early** — most studies are small or retrospective
2. **Combination logic matters** — itraconazole is mostly being explored as an adjunct
3. **Drug interaction review is essential** — itraconazole has meaningful CYP interaction relevance
4. **Long-term resistance questions remain open**
5. **Dosing in cancer settings differs from standard antifungal use**
### Bottom line
Itraconazole is a credible repurposed-drug candidate with real early oncology relevance. It should be understood as an investigational adjunct with multi-pathway promise, not as a proven replacement for standard treatment.
### Key References
Repurposing itraconazole for the treatment of cancer\
Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy\
Itraconazole as a Candidate for Drug Repurposing in Oncology\
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/evidence-summary.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.